Dr. Lanasa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Erwin Rd
Durham, NC 27705Phone+1 919-684-8964Fax+1 919-684-5325
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
University of Pittsburgh School of MedicineClass of 2002
Certifications & Licensure
MD State Medical License 2017 - 2019
NC State Medical License 2005 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Start of enrollment: 2007 May 10
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Start of enrollment: 2008 Jun 19
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsCommon variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes.Susan L. Slager, Nicola J. Camp, Lucia Conde, Tait D. Shanafelt, Sara J. Achenbach
British Journal of Haematology. 2012-12-01 - 127 citationsGenome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32Lucia Conde, Eran Halperin, Nicholas K. Akers, Kevin M. Brown, Karin E. Smedby
Nature Genetics. 2010-08-01 - 67 citationsActionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, Petra Mayer, S. Pützer
Nature Communications. 2018-02-15
Press Mentions
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell CarcinomaOctober 21st, 2024- FDA Approves 16 New Cancer Treatments as Global Cancer Rates SkyrocketOctober 4th, 2024
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, Including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ CancersSeptember 26th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
